PL424073A1 - Pochodne soli pirydyniowych, sposób uwalniania MNA oraz ich zastosowanie - Google Patents

Pochodne soli pirydyniowych, sposób uwalniania MNA oraz ich zastosowanie

Info

Publication number
PL424073A1
PL424073A1 PL424073A PL42407317A PL424073A1 PL 424073 A1 PL424073 A1 PL 424073A1 PL 424073 A PL424073 A PL 424073A PL 42407317 A PL42407317 A PL 42407317A PL 424073 A1 PL424073 A1 PL 424073A1
Authority
PL
Poland
Prior art keywords
mna
derivatives
application
release
releasing
Prior art date
Application number
PL424073A
Other languages
English (en)
Other versions
PL238932B1 (pl
Inventor
Stefan CHŁOPICKI
Kamil Kuś
Ivars Kalvinas
Victor Andrianov
Einars Loza
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL424073A priority Critical patent/PL238932B1/pl
Priority to PL18248109.3T priority patent/PL3505512T3/pl
Priority to EP18248109.3A priority patent/EP3505512B1/en
Publication of PL424073A1 publication Critical patent/PL424073A1/pl
Publication of PL238932B1 publication Critical patent/PL238932B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Zgłoszenie dotyczy pochodnych soli pirydyniowych stanowiących O-podstawione halogenki 3-oksymetyloaminokarbonylo-1-metylopirydyniowe oraz ich farmaceutyczne dopuszczalnych soli. Ujawnione związki mogą być stosowane jako leki w związku z zaobserwowanym uwalnianiem przez te związki substancji czynnej w postaci N1-metylo-nikotynamidu (MNA). Związki te mogą być stosowane zwłaszcza w leczeniu lub profilaktyce stanów chorobowych związanych z dysfunkcją śródbłonka naczyniowego. Zgłoszenie dotyczy także sposobu uwalniania MNA oraz zastosowania pochodnych soli pirydyniowych do selektywnego oznaczania i uwalniania MNA.
PL424073A 2017-12-31 2017-12-31 Pochodne soli pirydyniowych oraz ich zastosowanie PL238932B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL424073A PL238932B1 (pl) 2017-12-31 2017-12-31 Pochodne soli pirydyniowych oraz ich zastosowanie
PL18248109.3T PL3505512T3 (pl) 2017-12-31 2018-12-28 Pochodne soli pirydyniowych jako prekursory do uwalniania MNA
EP18248109.3A EP3505512B1 (en) 2017-12-31 2018-12-28 Quaternary nicotinamide derviatives as precursors for release of mna

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL424073A PL238932B1 (pl) 2017-12-31 2017-12-31 Pochodne soli pirydyniowych oraz ich zastosowanie

Publications (2)

Publication Number Publication Date
PL424073A1 true PL424073A1 (pl) 2019-07-01
PL238932B1 PL238932B1 (pl) 2021-10-18

Family

ID=65493778

Family Applications (2)

Application Number Title Priority Date Filing Date
PL424073A PL238932B1 (pl) 2017-12-31 2017-12-31 Pochodne soli pirydyniowych oraz ich zastosowanie
PL18248109.3T PL3505512T3 (pl) 2017-12-31 2018-12-28 Pochodne soli pirydyniowych jako prekursory do uwalniania MNA

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18248109.3T PL3505512T3 (pl) 2017-12-31 2018-12-28 Pochodne soli pirydyniowych jako prekursory do uwalniania MNA

Country Status (2)

Country Link
EP (1) EP3505512B1 (pl)
PL (2) PL238932B1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB675430A (en) * 1949-07-12 1952-07-09 Cilag Ltd Novel quaternary nicotinic acid amide derivatives and production thereof
WO2005067927A2 (en) * 2004-01-12 2005-07-28 Pharmena Sp Z O.O. The use of quaternary pyridinium salts as vasoprotective agents
WO2010000673A1 (en) * 2008-07-01 2010-01-07 Politechnika Lódzka N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases
US20150252027A1 (en) * 2012-10-05 2015-09-10 Sphaera Pharma Pte Ltd. Novel compounds, their synthesis and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB675430A (en) * 1949-07-12 1952-07-09 Cilag Ltd Novel quaternary nicotinic acid amide derivatives and production thereof
WO2005067927A2 (en) * 2004-01-12 2005-07-28 Pharmena Sp Z O.O. The use of quaternary pyridinium salts as vasoprotective agents
WO2010000673A1 (en) * 2008-07-01 2010-01-07 Politechnika Lódzka N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases
US20150252027A1 (en) * 2012-10-05 2015-09-10 Sphaera Pharma Pte Ltd. Novel compounds, their synthesis and their uses

Also Published As

Publication number Publication date
EP3505512B1 (en) 2022-03-09
EP3505512A1 (en) 2019-07-03
PL238932B1 (pl) 2021-10-18
PL3505512T3 (pl) 2022-07-25

Similar Documents

Publication Publication Date Title
PH12017501720A1 (en) Acid-addition salt of trk-inhibiting compound
HRP20250181T1 (hr) Spojevi i postupci za ciljanu razgradnju receptora androgena
HRP20250250T1 (hr) Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji
HK1258570A1 (zh) 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
BR112015006341A2 (pt) compostos, composição farmacêutica, método para tratar condição fibrótica, quantidade terapeuticamente efetiva de composto, de sal farmaceuticamente aceitável deste ou de composição farmacêutica e usos das mesmas e de compostos e/ou composição farmacêutica
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
HRP20210529T1 (hr) Inhibitori za mk2 i njihove uporabe
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2017014994A (es) Formulacion solida oral que contiene irinotecano y metodo de preparacion de la misma.
ZA201707096B (en) Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
MX394624B (es) Inhibidores selectivos hdac6, métodos de preparación y aplicación de los mismos.
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
AR106559A1 (es) Suspensión acuosa para administración oral y método para su preparación
EA201691741A1 (ru) Фармацевтическая композиция
HK1257171A1 (zh) 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
MX381611B (es) Derivados de c-glicósido que tienen anillos de fenilo condensado o sales farmacéuticamente aceptables de los mismos, método para prepararlos y composición farmacéutica que los contiene.
EP3898582A4 (en) NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY APPROVED SALT THEREOF, COMPOSITION THEREOF, AND METHODS OF USE THEREOF
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок
PL424073A1 (pl) Pochodne soli pirydyniowych, sposób uwalniania MNA oraz ich zastosowanie
EA201692045A1 (ru) Производное фенантролинфосфоновой кислоты и способ его получения и применения
MX2016014261A (es) Uso de acido 1,3-propandisulfonico o sales farmaceuticamente aceptables del mismo para el tratamiento de sarcoidosis.
MX389403B (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo